Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | LMNA | P02545 | 4/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eperisone SCHEMBL194769 | 1.00 | HRH3 (1.00) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Eperisone SCHEMBL218337 | 0.99 | HRH3 (0.97) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Inaperisone SCHEMBL250427 | 0.98 | HRH3 (0.97) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Inaperisone SCHEMBL3990438 | 0.97 | CHRM2 (0.94) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Inaperisone SCHEMBL1650087 | 0.96 | HRH3 (0.92) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Eperisone SCHEMBL2491287 | 0.93 | HRH3 (0.87) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Eperisone SCHEMBL1329969 | 0.93 | HRH3 (0.87) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Eperisone SCHEMBL1331476 | 0.92 | HRH3 (0.85) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Eperisone SCHEMBL2489151 | 0.92 | HRH3 (0.85) | HRH3CHRM2ADRA2BDRD3SIGMAR1 | |
| Eperisone SCHEMBL1331479 | 0.92 | HRH3 (0.85) | HRH3CHRM2ADRA2BDRD3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196895-A1 | NOVEL FORMS OF EPERISONE | BIONEVIA PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | claimed |
| US-20110281911-A1 | NOVEL FORMS OF EPERISONE | BIONEVIA PHARMACEUTICALS, INC. (US) | 2011-11-17 | — | — | US | claimed |
| EP-2379502-A2 | NOVEL FORMS OF EPERISONE | Bionevia Pharmaceuticals Inc. (US) | 2011-10-26 | — | — | EP | claimed |
| WO-2010081070-A2 | NOVEL FORMS OF EPERISONE | BIONEVIA PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | WO | claimed |
| WO-2010017135-A2 | NOVEL FORMS OF EPERISONE | BIONEVIA PHARMACEUTICALS, INC. (US) | 2010-02-11 | — | — | WO | claimed |
| WO-2012172413-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF EPERISONE AND DICLOFENAC AND PROCESS FOR PREPARING THEREOF | ABBOTT HEALTHCARE PVT. LTD. (IN) | 2012-12-20 | — | — | WO | disclosed |
| US-20120196895-A1 | NOVEL FORMS OF EPERISONE | BIONEVIA PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196895-A1 | NOVEL FORMS OF EPERISONE | BIONEVIA PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20110281911-A1 | NOVEL FORMS OF EPERISONE | BIONEVIA PHARMACEUTICALS, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281911-A1 | NOVEL FORMS OF EPERISONE | BIONEVIA PHARMACEUTICALS, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2379502-A2 | NOVEL FORMS OF EPERISONE | Bionevia Pharmaceuticals Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2379502-A2 | NOVEL FORMS OF EPERISONE | Bionevia Pharmaceuticals Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010081070-A3 | NOVEL FORMS OF EPERISONE | BIONEVIA PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010081070-A2 | NOVEL FORMS OF EPERISONE | BIONEVIA PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010081070-A2 | NOVEL FORMS OF EPERISONE | BIONEVIA PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010017135-A3 | NOVEL FORMS OF EPERISONE | BIONEVIA PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010017135-A2 | NOVEL FORMS OF EPERISONE | BIONEVIA PHARMACEUTICALS, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281911-A1 | NOVEL FORMS OF EPERISONE | PTGER1, PTGER2, PTGER3 | HRH3 3634/4885CHRM2 49/4885ADRA2B 588/4885 |
| US-20120196895-A1 | NOVEL FORMS OF EPERISONE | PTGER1, MTPN, PTGER2 | HRH3 3819/4885CHRM2 130/4885ADRA2B 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.